Search

Displaying results 2321 - 2330 of 8575 in total
  1. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    was 8.3 months. … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration

  2. Drug

    Tazemetostat

    go.drugbank.com/drugs/DB12887
    ApprovedInvestigational

    [L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]

  3. Drug

    Alatrofloxacin

    go.drugbank.com/drugs/DB09335
    ApprovedWithdrawn

    Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.

  4. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. … Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen.

  5. Drug

    Dextroamphetamine

    go.drugbank.com/drugs/DB01576
    ApprovedIllicitInvestigational

    Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

  6. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  7. Drug

    Anti-inhibitor coagulant complex

    go.drugbank.com/drugs/DB13151
    ApprovedInvestigational

    Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.

  8. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.

  9. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

  10. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.